A Review on Antiviral Activity of Favipiravir (original) (raw)
Related papers
Favipiravir: A new and emerging antiviral option in COVID-19
Medical Journal Armed Forces India, 2020
With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.
Favipiravir, will it be the Answer for the Specific Management of COVID-19?: A Review
Medico-Legal Update, 2021
Background: The COVID-19 has created havoc all over the world as no specific treatment available tilldate. Total COVID-19 cases had crossed 11,125,245 including 528,204 deaths as per the WHO data till 5July 2020. Unfortunately, India secured third place in total tally of COVID-19 cases with 6,77,719 totalcases including 19693 deaths as of 5th July 2020. The antiviral drug, Favipiravir, previously known as T-705approved in Japan for treatment of Influenza. It is selective & potent inhibitor of viral RNA polymerase. Itis promising drug for treatment of wide range of RNA viruses including SARSCoV-2.Method: The systematic review of Articles was done with the help of search engines like Embase, Medline,PubMed & Google Scholar, clinicaltrials.gov. The Peer reviewed articles published through 6th of July 2020were included in the study. This review was done to establish clinical evidence for use of Favipiravir inCOVID-19.Conclusion: It was found that due to lack of conclusive evidence, Favi...
IJRASET, 2021
Since last two years, whole world is going through the pandemic situation of Corona Virus Disease-19 (COVID-19). It caused more than 43 lakhs deaths worldwide. COVID-19 outbreak all over the world has led the researchers and Scientists to develop drugs or vaccines to prevent the spreading of this virus. Due to the unavailabity of proper drug treatment, various veterinary drugs are trying in humans. It is one of such type of antiviral drug which was previously used in treatment of viral infection in animals and birds. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.
New anti-viral drugs for the treatment of COVID-19 instead of favipiravir
Journal of Biomolecular Structure and Dynamics, 2020
The SARS-CoV-2 virus is a major problem in the world right now. Currently, all the attention of research centers and governments globally are focused on the investigation of vaccination studies and the discovery of small molecules that inhibit the SARS-CoV-2 virus in the treatment of patients. The goal of this study was to locate small molecules to be used against COVID19 instead of favipiravir. Favipiravir analogues were selected as drug candidates from the PubChem web tool. The RNA dependent RNA polymerase (RdRp) protein was selected as the target protein as favipiravir inhibits this protein in the human body. Initially, the inhibition activity of the studied compounds against RdRp of different virus types was investigated. Then, the inhibition properties of selected drug candidates and favipiravir were examined in detail against SARS-CoV-2 RdRp proteins. It was found that 2oxo-1H-pyrazine-3-carboxamide performed better than favipiravir in the results of molecular docking, molecular mechanics Poisson-Boltzmann surface area (MM-PSBA) calculations, and ADME analyses.
Role of favipiravir in the treatment of COVID-19
International Journal of Infectious Diseases, 2021
The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2. It has a wide therapeutic safety margin indicated by a wide CC50/EC50 ratio for a high dose. From the clinical studies in COVID-19, it has shown rapid viral clearance as compared to lopinavir/ritonavir (LPV/RTV) and superior recovery rate than umifenovir. Overall, favipiravir has shown promising results in clinical studies in China, Russia, and Japan, and more trials are underway in multiple countries, including USA, UK, and India. Recently, treatment guidelines from many countries and some states from India have included favipiravir in the treatment protocol. This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19.
Favipiravir and its potentials in COVID-19 pandemic: An update
Asian Pacific Journal of Tropical Medicine
The COVID-19 pandemic has caused millions of deaths and hundreds of millions of confirmed infections worldwide. This pandemic has prompted researchers to produce medications or vaccines to reduce or stop the progression and spread of this disease. A variety of previously licensed and marketed medications are being tested for the treatment and recurrence of SARS-CoV2, including favipiravir (Avigan). Favipiravir was recognized as an influenza antiviral drug in Japan in 2014, and has been known to have a potential in vitro activity against SARS-CoV-2, in addition to its broad therapeutic safety scope. Favipiravir was recently approved and officially used in many countries worldwide. Our review provides insights and up-to-date knowledge of the current role of favipiravir in the treatment of COVID-19 infection, focusing on preclinical and ongoing clinical trials, evidence of its efficacy against SARS-CoV-2 in COVID-19, side effects, anti-viral mechanism, and the pharmacokinetic properties of the drug in the treatment of COVID-19. Due to its teratogenic effects, favipiravir cannot be offered to expectant or pregnant mothers. The practical efficacy of such an intervention regimen will depend on its dose, treatment duration, and cost as well as difficulties in application.
Favipiravir Efficacy and Safety for the Treatment of Severe Coronavirus 2019. A Retrospective Study
Journal of Ayub Medical College Abbottabad
Background: Corona virus disease is caused by the enveloped, single stranded RNA virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becoming the deadliest disease of the century. Its global outbreak has led researchers to develop drugs or vaccines to prevent the spread of the disease. Favipiravir is an approved orally administered antiviral drug that selectively inhibits RNA-dependent RNA polymerase, used off-label to treat COVID-19. Objectives: The purpose of this study was to assess the efficacy and safety of this drug for severe COVID-19 infection. Methods: This was an observational retrospective study, carried out at the ICU of King Saud Medical City (KSMC) from June 2020 to August 2020. Including a total of one thousand six hundred and ninety-nine patients (n=1699). Categorized into a treatment group (193 patients) who received Favipiravir along with standard care, and non-treatment group (1506 patients) who received standard care only. Results: ICU all...
Use of favipiravir against Covid-19: A Review
Pakistan BioMedical Journal, 2022
Coronavirus disease 2019 (COVID-19) emerged as a global challenge for the world healthcare community. The use of favipiravir against COVID-19 was studied in various studies but its efficacy and side effects remain uncertain. Therefore, we aimed to analyze the use of favipiravir in patients suffering from coronavirus.The literature search was done by using several databases including MEDLINE, Google Scholar, Web of Science, PubMed, and Science Direct. To ensure the credibility and accuracy of the included articles we include only those studies that were published in indexed journals. Furthermore, in this current review, we mainly include only those studies published from January 2015 to September2021. We included all the review and research articles published in the English language.The review of currently available literature suggests the use of favipiravir showed both some utility and side effects in patients diagnosed with coronavirus-19. Moreover, the use of this antiviral drug ...
Ciencia and Engenharia/ Science and Engineering Journal , 2020
In the present scenario the outbreak of a deadly virus called corona virus has caused the COVID-19 disease in the world. This disease has been declared a pandemic by WHO as the ill effects of this infectious disease are prevalent throughout the world. The corona virus was first discovered in the Wuhan city of China in 2019. This virus being the contagious in nature took over the entire world in a span of few months. Now, in order to deal with this virus, many researches are going on to find either a vaccine or some cure for this virus. The anti-viral medicine called Favipiravir is one such medicine that is being extensively studied for its probable use in treatment for this virus. Favipiravir was first introduced in Japan in 2014 as a cure for influenza. After that research on this medicine also revealed that it is a broad spectrum medicine and can be used in treatment of many viral diseases. The potential use of Favipiravir as a cure for COVID-19 is also under study and research. The results till now have suggested that the medicine Favipiravir may give some symptomatic relief in case of corona virus infection but it cannot cure the disease completely. In this paper the nature of the Favipiravir medicine will be discussed along with its potential to be used as a symptomatic relief medicine in the infection of COVID-19.
Effectiveness of Antiviral Drugs as Covid-19 Therapy
2021
SARS-CoV 2 firstly emerged in China on December 2019 and it was spreading rapidly across the world until now. At this time, there is no vaccine or medication approved by the FDA. However, there are some FDA approved medicines for treating other diseases that can be used for Covid-19 based on tests. This review focuses on therapy efficacy, work mechanism, pharmacokinetic profile, safety, and future perspective. Article review related to therapy on Covid-19 patients, particularly antiviral therapy which was the combination of lopinavir and ritonavir, chloroquine, hydroxychloroquine, remdesivir, and favipiravir. The reviewed relevant articles were observational study, in vitro test, case report, and clinical test. A total of 13 articles met the requirement, 9 articles discussed the result of therapy during the medication of COVID-19 patients, 2 reports of in vitro test, and 2 results of clinical trials. From several studies that had been conducted, remdesivir, combination of lopinavir ...